NCT03568942View on ClinicalTrials.gov

Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis)

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 23, 2018

Primary Completion Date

January 7, 2019

Study Completion Date

January 7, 2019

Conditions
Infections, Bacterial
Interventions
DRUG

Gepotidacin

Gepotidacin tablets will be available at a dose strength of 750 mg. Tablets will be administered BID with water after consumption of food.

Trial Locations (1)

91942

GSK Investigational Site, La Mesa

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

GlaxoSmithKline

INDUSTRY

NCT03568942 - Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis) | Biotech Hunter | Biotech Hunter